Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shares of Stryker Corporation (SYK - Analyst Report) achieved a new 52-week high, touching $67.36 on May 9, which is above its previous level of $67.15, and closed at $67.01 on the same date. The closing price of this orthopedic devices giant represented a solid one-year return of 27.7% and year-to-date return of 20.4%.

Average volume of shares traded over the last 3 months came in at approximately 1,562K. Currently, the stock trades at a forward P/E of 15.96x, above its peer group P/E of 14.43x.

Growth Drivers

Impressive first-quarter 2013 results, including an earnings surprise of 1.98% and the recent completion of the acquisition of a leading China-based trauma manufacturing company, Trauson Holdings, were the primary growth drivers for Stryker.

On Apr 24, Stryker reported its first-quarter earnings per share of $1.03 beating the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 4.0%. Organic revenue growth along with cost curtailment efforts by the company’s global quality and operations group led to the year-over-year growth.

Stryker’s strong business fundamentals, well-diversified product portfolio and expanding foothold in emerging markets through acquisitions are expected to drive future growth. Moreover, the company remains committed to delivering incremental return to investors via share repurchase and dividends.

Recently, in Mar 2013, it completed the acquisition of a leading China-based trauma manufacturing company, Trauson Holdings. Stryker acquired this entity in an effort to strengthen its foothold in the Chinese orthopedic market.

Stryker, with a market-cap of $25.33 billion, is one of the world’s largest medical device manufacturers operating in the global orthopedic market. The recent stability in the domestic recon market and turnaround of its European business should improve results in 2013.

Stocks to Consider

Stryker carries a Zacks Rank #3 (Hold). With Stryker’s shares trading at all-time highs, any upside from here may be limited. Other medical stocks such as Conceptus , TG Therapeutics (TGTX - Snapshot Report) and AtriCure (ATRC - Snapshot Report) warrant a look. While Conceptus carries a Zacks Rank #1 (Strong Buy), the other two stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%